Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online - 114
- California: Governor Newsom announces new tax credits that will generate $2.1 billion investment in world's 4th largest economy
- New PSA Campaign to Address Black Maternal and Infant Mortality in Los Angeles County
YANTAI, China, Feb. 15, 2025 ~ At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, USA, Professor Xinan Sheng from Peking University Cancer Hospital presented the latest data from a phase II clinical trial of Disitamab Vedotin (DV) in combination with Toripalimab as a neoadjuvant therapy for HER2-expressing muscle-invasive bladder cancer (MIBC). This marks the first time that results from a prospective clinical study investigating an ADC drug in combination with an immunotherapy have been publicly disclosed.
The study, known as NCT05297552 and identified as Study ID: RC48-C017, explored the potential synergy between targeted therapy and immunotherapy in the perioperative setting for MIBC. It specifically evaluated the safety and efficacy of combining DV, a HER2-targeting ADC drug developed by RemeGen Co., Ltd. (RemeGen), with Toripalimab, a PD-1 inhibitor.
In May 2024, based on the preliminary results of this study, China's National Medical Products Administration (NMPA) granted breakthrough therapy designation to DV. These initial findings were also presented at the 2024 ASCO Annual Meeting and generated significant interest among experts worldwide. The updated data presented at ASCO GU further confirmed the promising clinical benefits of this therapeutic approach.
More on The Californer
The NCT05297552 study included 47 eligible patients, with 10.6% having HER2 IHC 1+, 57.4% having IHC 2+, and 31.9% having IHC 3+. Of these patients, 33 underwent radical cystectomy and pelvic lymph node dissection (RC + PLND). As of December 3, 2024, when the data was cut off, the study showed impressive efficacy and manageable safety profiles:
- The pathological complete response (pCR) rate was 63.6%, nearly double that of traditional neoadjuvant chemotherapies (36%-42%). The overall pathological response rate was 75.8%. Notably, for patients with a baseline clinical stage of T2N0, the postoperative pCR rate reached 85.7%. Additionally, a pCR rate of 55.6% was achieved in patients with other pathological subtypes of urothelial carcinoma at baseline. These results were consistent regardless of PD-L1 status or HER2 expression level (IHC 1+/2+/3+), with a pCR rate of 84.6% observed in patients with HER2 IHC 3+.
- The 12-month event-free survival (EFS) rate for all patients who underwent radical cystectomy was 92.5%, and the 18-month EFS rate was 85.9%.
- The therapy demonstrated a manageable safety profile, with only 27.7% of patients experiencing grade 3 or higher treatment-emergent adverse events (TEAEs). This is significantly lower than the incidence seen with traditional chemotherapy regimens (40%-50%), indicating a favorable tolerability.
More on The Californer
RemeGen is committed to advancing research on targeted and personalized therapies for bladder cancer through expanding indications and innovating new therapies using DV. The company aims to provide more potent treatment options for bladder cancer patients worldwide. Currently, studies are underway to explore the feasibility of using DV-based regimens as first-line treatment for locally advanced or metastatic urothelial cancer. There are also plans to expand research on DV as a neoadjuvant therapy for MIBC throughout the entire perioperative period and investigate its potential synergy with chemotherapy or other immunotherapies in treating urothelial cancer.
ASCO GU is one of the top conferences in urologic oncology, attracting leading experts from around the world. The presentation of the NCT05297552 study results at this prestigious event highlights the significance and potential impact of this novel combination therapy for MIBC. With further research and development, DV in combination with Toripalimab could potentially revolutionize the treatment landscape for HER2-expressing MIBC.
The study, known as NCT05297552 and identified as Study ID: RC48-C017, explored the potential synergy between targeted therapy and immunotherapy in the perioperative setting for MIBC. It specifically evaluated the safety and efficacy of combining DV, a HER2-targeting ADC drug developed by RemeGen Co., Ltd. (RemeGen), with Toripalimab, a PD-1 inhibitor.
In May 2024, based on the preliminary results of this study, China's National Medical Products Administration (NMPA) granted breakthrough therapy designation to DV. These initial findings were also presented at the 2024 ASCO Annual Meeting and generated significant interest among experts worldwide. The updated data presented at ASCO GU further confirmed the promising clinical benefits of this therapeutic approach.
More on The Californer
- NBA Champion Lamar Odom Launches Anti-Addiction Meme Coin, Ushering in a Disruptive Innovation in Web3
- Emmetra Partners with Renesas to Advance Agentic AI-Powered Imaging Solutions
- Gravity to Bring 5-Minute EV Charging to 8 Sites Across Greater LA
- California: Governor Newsom issues statement on Pope Leo XIV, the first American Pope
- New poll shows high rates of employee burnout amid concerns over politics and personal finances
The NCT05297552 study included 47 eligible patients, with 10.6% having HER2 IHC 1+, 57.4% having IHC 2+, and 31.9% having IHC 3+. Of these patients, 33 underwent radical cystectomy and pelvic lymph node dissection (RC + PLND). As of December 3, 2024, when the data was cut off, the study showed impressive efficacy and manageable safety profiles:
- The pathological complete response (pCR) rate was 63.6%, nearly double that of traditional neoadjuvant chemotherapies (36%-42%). The overall pathological response rate was 75.8%. Notably, for patients with a baseline clinical stage of T2N0, the postoperative pCR rate reached 85.7%. Additionally, a pCR rate of 55.6% was achieved in patients with other pathological subtypes of urothelial carcinoma at baseline. These results were consistent regardless of PD-L1 status or HER2 expression level (IHC 1+/2+/3+), with a pCR rate of 84.6% observed in patients with HER2 IHC 3+.
- The 12-month event-free survival (EFS) rate for all patients who underwent radical cystectomy was 92.5%, and the 18-month EFS rate was 85.9%.
- The therapy demonstrated a manageable safety profile, with only 27.7% of patients experiencing grade 3 or higher treatment-emergent adverse events (TEAEs). This is significantly lower than the incidence seen with traditional chemotherapy regimens (40%-50%), indicating a favorable tolerability.
More on The Californer
- Tessellations Appoints Luthern Williams as Head of School
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- Psychological Thriller "Killing Off Connor" To Open 34th IFS Film Fest After 12-years In Post
- Harvest Properties Acquires Two San Francisco Bay Area Self Storage Facilities for $44.2 Million
- California businesses in near-universal compliance with prohibition of intoxicating hemp products harmful to youth
RemeGen is committed to advancing research on targeted and personalized therapies for bladder cancer through expanding indications and innovating new therapies using DV. The company aims to provide more potent treatment options for bladder cancer patients worldwide. Currently, studies are underway to explore the feasibility of using DV-based regimens as first-line treatment for locally advanced or metastatic urothelial cancer. There are also plans to expand research on DV as a neoadjuvant therapy for MIBC throughout the entire perioperative period and investigate its potential synergy with chemotherapy or other immunotherapies in treating urothelial cancer.
ASCO GU is one of the top conferences in urologic oncology, attracting leading experts from around the world. The presentation of the NCT05297552 study results at this prestigious event highlights the significance and potential impact of this novel combination therapy for MIBC. With further research and development, DV in combination with Toripalimab could potentially revolutionize the treatment landscape for HER2-expressing MIBC.
Filed Under: Business
0 Comments
Latest on The Californer
- Long Beach: City Celebrates Inaugural National Home Improvement Month: Love Where You Live
- California sues Trump administration for illegally withholding billions in bipartisan infrastructure funds: 'Another Trump gift to China'
- Tale of two trains: California high-speed rail leaves Texas in the dust
- California: State invests nearly $33 billion in cap-and-trade dollars to make communities cleaner and healthier
- Where AI Falls Short, Real Connections Rise—Media Outreach with Heart
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- EY US unveils Puneet Nanda of GuruNanda as an Entrepreneur Of The Year® 2025 Award Finalist
- California: Governor Newsom proclaims Children's Mental Health Awareness Week 2025
- VC Mastermind Launches: A Private Global Network and Podcast for Top-Tier Venture Capital Leaders
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Actor and Writer Ernie Rivera Launches Groundbreaking Indie Superhero Thriller, Citadel Lost, with Full Campaign and Industry Buzz
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- ViroMissile Unveils IDOV™ Platform: A Potential One-Shot Cure for Cancer
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Expert Tongue-Tie and Lip-Tie Treatment Now Available at SVPD and Orthodontics